Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 69Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 48Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 35Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Biliary Tract Neoplasms 29Neoplasms 28Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Liver Neoplasms 18Head and Neck Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 14Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Oxaliplatin 11Mitomycin 10Leucovorin 7Irinotecan 6Fluorouracil 6Hyperthermic Intraperitoneal Chemotherapy 5Capecitabine 4Surveys and Questionnaires 3Cytoreduction Surgical Procedures 3Cisplatin 3dehydroftorafur 2Trastuzumab 2Thalidomide 2Mitozytrex 2Melphalan 2Interleukin-12 Subunit p35 2Floxuridine 2Doxorubicin 2Cetuximab 2Biopsy 2tipifarnib 1surufatinib 1sodium thiosulfate 1sintilimab 1nintedanib 1nilotinib 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Appendiceal Neoplasms × durvalumab × Clear all
NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Ludwig Institute for Cancer Research

Phase 1/2 Completed
67 enrolled 16 charts
GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡